Bristol Myers Squibb Presents Sotyktu Data in PsA at 2025 AAD
Significantly more patients treated with Sotyktu achieved ACR and PASI response rates and had greater improvements in patient-reported quality of life compared with placebo at Week 16 Sotyktu was...